Grant: Engage Grants Program
University of British Columbia
$25,000.00
Applying a novel therapeutic strategy to membrane protein targets of a pathogen
FY 2016-17
Summary
Salmonella infections represent a significant public health concern and disease burden. Significant sources ofinfection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control ofSalmonella infections in poultry products is one means to reduce human infections. While advances have beenmade in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressureon commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities.NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy thatcould be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvestpoultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and arebeing tested for their efficacy using in vitro and in vivo methods. The work proposed here capitalizes on theexpertise of Dr. Eric Accili in the fields of membrane biology, ion channel biology, microscopy, andgastrointestinal (GI) tract biology. This project proposes to: (1) prototype strategies for the purification ofNovoBind's membrane protein targets, (2) develop in vitro functional assays for these targets to test leadmolecules in. In addition, Dr. Accili will provide his expertise to the design of future ex vivo models. Thedevelopment of a Salmonella-selective and highly effective antibody would benefit Canadian and Worldpopulations by reducing human infection and illness, loss of life and costs of treatment. The revenue generatedby NovoBind in delivering this product would also be an economic boost to Canada.
Program
Engage Grants Program
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
503585-2016
Name nom
Accili, Eric
Department département
Cellular and Physiological Sciences
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1209
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Agriculture
Area of application fr
Agriculture
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Partie
1
Nb partie
1
Application title
Applying a novel therapeutic strategy to membrane protein targets of a pathogen
Keyword
NSERC
Application summary
Salmonella infections represent a significant public health concern and disease burden. Significant sources ofinfection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control ofSalmonella infections in poultry products is one means to reduce human infections. While advances have beenmade in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressureon commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities.NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy thatcould be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvestpoultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and arebeing tested for their efficacy using in vitro and in vivo methods. The work proposed here capitalizes on theexpertise of Dr. Eric Accili in the fields of membrane biology, ion channel biology, microscopy, andgastrointestinal (GI) tract biology. This project proposes to: (1) prototype strategies for the purification ofNovoBind's membrane protein targets, (2) develop in vitro functional assays for these targets to test leadmolecules in. In addition, Dr. Accili will provide his expertise to the design of future ex vivo models. Thedevelopment of a Salmonella-selective and highly effective antibody would benefit Canadian and Worldpopulations by reducing human infection and illness, loss of life and costs of treatment. The revenue generatedby NovoBind in delivering this product would also be an economic boost to Canada.